Author:
Almeida Antonio M.,Pierdomenico Francesca
Subject
Cancer Research,Oncology,Hematology
Reference7 articles.
1. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study;Fenaux;Lancet Oncol,2009
2. Vidaza summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000978/WC500050239.pdf [accessed 21.02.12].
3. Prescribing information for Vidaza. Available from: http://www.vidaza.com/pdf/PI_FINAL.pdf [accessed 21.02.12].
4. Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes;Silverman;Cancer,2011
5. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine;Santini;Eur J Haematol,2010
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献